CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
3.7.Regulatory Guidelines
3.8.Value Chain Analysis
3.9.Market Share Analysis
3.10.Key Regulation Analysis
3.11.Patent Landscape
CHAPTER 4: LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY PRODUCT
4.1 Overview
4.1.1 Market size and forecast
4.2 Endocardial LAA Devices
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Epicardial LAA Devices
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
CHAPTER 5: LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY END USE
5.1 Overview
5.1.1 Market size and forecast
5.2 Hospitals
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Ambulatory Surgery Centers
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Others
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
CHAPTER 6: LEFT ATRIAL APPENDAGE (LAA) CLOSURE DEVICE MARKET, BY REGION
6.1 Overview
6.1.1 Market size and forecast
6.2 North America
6.2.1 Key trends and opportunities
6.2.2 North America Market size and forecast, by Product
6.2.3 North America Market size and forecast, by End Use
6.2.4 North America Market size and forecast, by country
6.2.4.1 U.S.
6.2.4.1.1 Market size and forecast, by Product
6.2.4.1.2 Market size and forecast, by End Use
6.2.4.2 Canada
6.2.4.2.1 Market size and forecast, by Product
6.2.4.2.2 Market size and forecast, by End Use
6.2.4.3 Mexico
6.2.4.3.1 Market size and forecast, by Product
6.2.4.3.2 Market size and forecast, by End Use
6.3 Europe
6.3.1 Key trends and opportunities
6.3.2 Europe Market size and forecast, by Product
6.3.3 Europe Market size and forecast, by End Use
6.3.4 Europe Market size and forecast, by country
6.3.4.1 Germany
6.3.4.1.1 Market size and forecast, by Product
6.3.4.1.2 Market size and forecast, by End Use
6.3.4.2 United Kingdom
6.3.4.2.1 Market size and forecast, by Product
6.3.4.2.2 Market size and forecast, by End Use
6.3.4.3 France
6.3.4.3.1 Market size and forecast, by Product
6.3.4.3.2 Market size and forecast, by End Use
6.3.4.4 Spain
6.3.4.4.1 Market size and forecast, by Product
6.3.4.4.2 Market size and forecast, by End Use
6.3.4.5 Italy
6.3.4.5.1 Market size and forecast, by Product
6.3.4.5.2 Market size and forecast, by End Use
6.3.4.6 Rest of Europe
6.3.4.6.1 Market size and forecast, by Product
6.3.4.6.2 Market size and forecast, by End Use
6.4 Asia-Pacific
6.4.1 Key trends and opportunities
6.4.2 Asia-Pacific Market size and forecast, by Product
6.4.3 Asia-Pacific Market size and forecast, by End Use
6.4.4 Asia-Pacific Market size and forecast, by country
6.4.4.1 China
6.4.4.1.1 Market size and forecast, by Product
6.4.4.1.2 Market size and forecast, by End Use
6.4.4.2 Japan
6.4.4.2.1 Market size and forecast, by Product
6.4.4.2.2 Market size and forecast, by End Use
6.4.4.3 India
6.4.4.3.1 Market size and forecast, by Product
6.4.4.3.2 Market size and forecast, by End Use
6.4.4.4 South Korea
6.4.4.4.1 Market size and forecast, by Product
6.4.4.4.2 Market size and forecast, by End Use
6.4.4.5 Australia
6.4.4.5.1 Market size and forecast, by Product
6.4.4.5.2 Market size and forecast, by End Use
6.4.4.6 Rest Of Asia Pacific
6.4.4.6.1 Market size and forecast, by Product
6.4.4.6.2 Market size and forecast, by End Use
6.5 LAMEA
6.5.1 Key trends and opportunities
6.5.2 LAMEA Market size and forecast, by Product
6.5.3 LAMEA Market size and forecast, by End Use
6.5.4 LAMEA Market size and forecast, by country
6.5.4.1 Brazil
6.5.4.1.1 Market size and forecast, by Product
6.5.4.1.2 Market size and forecast, by End Use
6.5.4.2 Saudi Arabia
6.5.4.2.1 Market size and forecast, by Product
6.5.4.2.2 Market size and forecast, by End Use
6.5.4.3 UAE
6.5.4.3.1 Market size and forecast, by Product
6.5.4.3.2 Market size and forecast, by End Use
6.5.4.4 South Africa
6.5.4.4.1 Market size and forecast, by Product
6.5.4.4.2 Market size and forecast, by End Use
6.5.4.5 Rest of LAMEA
6.5.4.5.1 Market size and forecast, by Product
6.5.4.5.2 Market size and forecast, by End Use
CHAPTER 7: COMPANY LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Key developments
CHAPTER 8: COMPANY PROFILES
8.1 sentreheart, inc.
8.1.1 Company overview
8.1.2 Company snapshot
8.1.3 Operating business segments
8.1.4 Product portfolio
8.1.5 Business performance
8.1.6 Key strategic moves and developments
8.2 Boston Scientific Corporation
8.2.1 Company overview
8.2.2 Company snapshot
8.2.3 Operating business segments
8.2.4 Product portfolio
8.2.5 Business performance
8.2.6 Key strategic moves and developments
8.3 AtriCure, Inc.
8.3.1 Company overview
8.3.2 Company snapshot
8.3.3 Operating business segments
8.3.4 Product portfolio
8.3.5 Business performance
8.3.6 Key strategic moves and developments
8.4 Abbott Laboratories
8.4.1 Company overview
8.4.2 Company snapshot
8.4.3 Operating business segments
8.4.4 Product portfolio
8.4.5 Business performance
8.4.6 Key strategic moves and developments
8.5 Occlutech
8.5.1 Company overview
8.5.2 Company snapshot
8.5.3 Operating business segments
8.5.4 Product portfolio
8.5.5 Business performance
8.5.6 Key strategic moves and developments
8.6 lifetech scientific corporation
8.6.1 Company overview
8.6.2 Company snapshot
8.6.3 Operating business segments
8.6.4 Product portfolio
8.6.5 Business performance
8.6.6 Key strategic moves and developments
8.7 Cardia, Inc.
8.7.1 Company overview
8.7.2 Company snapshot
8.7.3 Operating business segments
8.7.4 Product portfolio
8.7.5 Business performance
8.7.6 Key strategic moves and developments
8.8 Aegis Medical Group.
8.8.1 Company overview
8.8.2 Company snapshot
8.8.3 Operating business segments
8.8.4 Product portfolio
8.8.5 Business performance
8.8.6 Key strategic moves and developments
8.9 Biosense Webster, Inc.
8.9.1 Company overview
8.9.2 Company snapshot
8.9.3 Operating business segments
8.9.4 Product portfolio
8.9.5 Business performance
8.9.6 Key strategic moves and developments
8.10 Johnson & Johnson Services, Inc.
8.10.1 Company overview
8.10.2 Company snapshot
8.10.3 Operating business segments
8.10.4 Product portfolio
8.10.5 Business performance
8.10.6 Key strategic moves and developments
世界の左心耳（LAA）閉鎖装置市場2021-2031：製品別（心内膜LAA装置、心外膜LAA装置）、エンドユーザー別 |
| 【英語タイトル】Left Atrial Appendage (LAA) Closure Device Market By Product (Endocardial LAA Devices, Epicardial LAA Devices), By End Use (Hospitals, Ambulatory Surgery Centers, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031 | |
 | ・商品コード：ALD23JN027 ・発行会社（調査会社）：Allied Market Research ・発行日：2022年9月 ・ページ数：318 ・レポート言語：英語 ・レポート形式：PDF ・納品方法：Eメール（受注後24時間以内） ・調査対象地域：グローバル ・産業分野：医療 |
| Single User | USD5,730 ⇒換算￥744,900 | 見積依頼/購入/質問フォーム |
| 5 User | USD6,450 ⇒換算￥838,500 | 見積依頼/購入/質問フォーム |
| Enterprise User | USD9,600 ⇒換算￥1,248,000 | 見積依頼/購入/質問フォーム |
|
※販売価格オプションの説明 ※お支払金額：換算金額（日本円）＋消費税 ※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡） ※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能） |
| Allied Market Research社の本調査資料では、2021年に13億ドルであった世界の左心耳（LAA）閉鎖装置市場規模が、2031年までに82億ドルに拡大し、2022年から2031年の間に年平均21%で成長すると予想しています。本資料は、左心耳（LAA）閉鎖装置の世界市場について調べ、イントロダクション、エグゼクティブサマリー、市場概要、製品別（心内膜LAA装置、心外膜LAA装置）分析、エンドユーザー別（病院、外来手術センター、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米・中東・アフリカ）分析、企業状況、企業情報などの項目を掲載しております。また、sentreheart, inc.、Boston Scientific Corporation、AtriCure, Inc.、Abbott Laboratories、Occlutech、lifetech scientific corporation、Cardia, Inc.、Aegis Medical Group.などの企業情報が含まれています。 ・イントロダクション ・エグゼクティブサマリー ・市場概要 ・世界の左心耳（LAA）閉鎖装置市場規模：製品別 -心内膜LAA装置の市場規模 -心外膜LAA装置の市場規模 ・世界の左心耳（LAA）閉鎖装置市場規模：エンドユーザー別 -病院における市場規模 -外来手術センターにおける市場規模 -その他における市場規模 ・世界の左心耳（LAA）閉鎖装置市場規模：地域別 - 北米の左心耳（LAA）閉鎖装置市場規模 - ヨーロッパの左心耳（LAA）閉鎖装置市場規模 - アジア太平洋の左心耳（LAA）閉鎖装置市場規模 - 中南米・中東・アフリカの左心耳（LAA）閉鎖装置市場規模 ・企業状況 ・企業情報 |
The global left atrial appendage (LAA) closure device market is envisioned to garner $8,218.10 million by 2031, growing from $1,276.90 million in 2021 at a CAGR of 20.97% from 2022 to 2031.
The global Left Atrial Appendage (LAA) Closure device is implanted in the heart and is intended to reduce the risk of thromboembolism from the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation. The device mechanically occludes the LAA to prevent LAA thrombus from entering the circulation of the blood in the body. LAA closure reduces the stroke risk associated with atrial fibrillation. But, it doesn’t treat the AFib itself. Left atrial appendage closure can benefit people who need heart surgery and also have atrial fibrillation. The procedure is also helpful for those who have atrial fibrillation.
The rising prevalence of atrial fibrillation is anticipated to augment the need for left atrial appendage closure devices. Atrial fibrillation was one the most prevalent atrial arrhythmia in patients suffering from congenital heart disease. Additionally, the aging population will increase atrial fibrillation disease incidences, as elderly adults are more susceptible to arrhythmia, ischemic stroke disease, and atrial fibrillation. Such factors are anticipated to drive the Left Atrial Appendage (LAA) Closure device market value.
However, the availability of alternatives and the high cost of left atrial appendage atrial closure devices may negatively impact the market expansion. Oral anticoagulation is the conventional alternative to left atrial appendage closure devices and is extensively preferred by doctors with non-valvular atrial fibrillation. The development of non-vitamin oral anticoagulants (NOACs) such as rivaroxaban, dabigatran, apixaban, and edoxaban have facilitated the use of oral anti-coagulants among patients that are susceptible to thromboembolic events in stroke management. Such factors are anticipated to restrict the Left Atrial Appendage (LAA) Closure device market growth.
The COVID-19 pandemic brought several uncertainties leading to severe economic losses as various businesses across the world were at a standstill. There were import-export restrictions laid down on major Left Atrial Appendage (LAA) Closure device-producing countries such as the United States and China, which imposed significant challenges on the market. COVID-19 virus enhances the thrombo-inflammatory cascade, which intensifies coagulation and may increase the risk of cardiac embolism in patients with AF. The limitations regarding the ICU beds during the pandemic represent a major restriction in performing heart surgeries including left atrial appendage closure procedures, thereby reducing the usage of left atrial appendage closure devices.
The key players profiled in the Left Atrial Appendage (LAA) Closure Device market report include Boston Scientific Corporation, Abbott, Lifetech Scientific, ATRICURE, INC., SentreHEART, Inc., Medical Device Business Services, Inc., Occlutech, Cardia, Inc., Johnson & Johnson Private Limited, and Lepu Medical Technology Co., Ltd.
Key Benefits For Stakeholders
●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the left atrial appendage (LAA) closure device market analysis from 2021 to 2031 to identify the prevailing left atrial appendage (LAA) closure device market opportunities.
●Market research is offered along with information related to key drivers, restraints, and opportunities.
●Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders to make profit-oriented business decisions and strengthen their supplier-buyer network.
●An in-depth analysis of the left atrial appendage (LAA) closure device market segmentation assists to determine the prevailing market opportunities.
●Major countries in each region are mapped according to their revenue contribution to the global market.
●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
●The report includes the analysis of the regional as well as global left atrial appendage (LAA) closure device market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Product
● Endocardial LAA Devices
● Epicardial LAA Devices
By End Use
● Hospitals
● Ambulatory Surgery Centers
● Others
By Region
● North America
○ U.S.
○ Canada
○ Mexico
● Europe
○ Germany
○ United Kingdom
○ France
○ Spain
○ Italy
○ Rest of Europe
● Asia-Pacific
○ China
○ Japan
○ India
○ South Korea
○ Australia
○ Rest Of Asia Pacific
● LAMEA
○ Brazil
○ Saudi Arabia
○ UAE
○ South Africa
○ Rest of LAMEA
● Key Market Players
○ sentreheart, inc.
○ Boston Scientific Corporation
○ AtriCure, Inc.
○ Abbott Laboratories
○ Occlutech
○ lifetech scientific corporation
○ Cardia, Inc.
○ Aegis Medical Group.
○ Biosense Webster, Inc.
○ Johnson & Johnson Services, Inc.
| ★調査レポート[世界の左心耳（LAA）閉鎖装置市場2021-2031：製品別（心内膜LAA装置、心外膜LAA装置）、エンドユーザー別] (コード：ALD23JN027)販売に関する免責事項を必ずご確認ください。 |
| ★調査レポート[世界の左心耳（LAA）閉鎖装置市場2021-2031：製品別（心内膜LAA装置、心外膜LAA装置）、エンドユーザー別]についてメールでお問い合わせ |
